Stereotaxis (NYSEAMERICAN:STXS – Get Rating) announced its quarterly earnings results on Tuesday. The company reported ($0.06) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.06), MarketWatch Earnings reports. Stereotaxis had a negative net margin of 30.60% and a negative return on equity of 30.70%.
Stereotaxis stock traded down $0.08 on Wednesday, reaching $1.83. The company’s stock had a trading volume of 24,474 shares, compared to its average volume of 304,153. The firm has a market cap of $136.60 million, a P/E ratio of -11.63 and a beta of 1.74. Stereotaxis has a twelve month low of $1.88 and a twelve month high of $10.30.
Separately, Zacks Investment Research raised shares of Stereotaxis from a “sell” rating to a “hold” rating in a research report on Thursday, May 5th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, Stereotaxis presently has a consensus rating of “Buy” and an average target price of $10.20.
About Stereotaxis (Get Rating)
Stereotaxis, Inc designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites.
- Get a free copy of the StockNews.com research report on Stereotaxis (STXS)
- Wendy’s Growth Story Has Come To An End
- Can Six Flags(SIX) or Cedar Fair (FUN) Give Investors a Thrill Later This Year?
- Beyond Meat Could Sizzle After Q1 Results Are Released
- Inflation Hasn’t Peaked At Reynolds Consumer Products
- Is Now The Time To Buy Coinbase (NASDAQ: COIN)?
Receive News & Ratings for Stereotaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stereotaxis and related companies with MarketBeat.com's FREE daily email newsletter.